NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
Fate Therapeutics
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center